Master dataINID | Criterion | Field | Content |
---|
| Type of IP right | SART | Patent |
| Status | ST | Pending/in force |
21 | DE file number | DAKZ | 60 2010 049 210.9 |
96 | EP file number | EAKZ | 10 80 6936.0 |
86 | WO file number | WAKZ | PCT/US2010/043586 |
97 | EP publication number | EPN | 2459212 |
87 | WO publication number | WPN | 2011017177 |
54 | Designation/title | TI | ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON MORBUS GAUCHER |
51 | IPC main class | ICM (ICMV) | A61K 38/47 (2006.01) |
51 | IPC secondary class(es) | ICS (ICSV) | G01N 33/68 (2006.01) |
22 | DE application date | DAT | Jul 28, 2010 |
96 | EP application date | EAT | Jul 28, 2010 |
86 | WO application date | WAT | Jul 28, 2010 |
43 | Date of first publication | OT | Feb 10, 2011 |
| Date of publication of grant | PET | Mar 14, 2018 |
71/73 | Applicant/owner | INH | Takeda Pharmaceutical Company Limited, Osaka-shi, Osaka, JP |
72 | Inventor | IN | DANIEL, Peter, F., NatickMA 01760, US; HEARTLEIN, Michael, W., BoxboroughMA 01719, US |
74 | Representative | VTR | Müller-Boré & Partner Patentanwälte PartG mbB, 80639 München, DE |
| Address for service | | Müller-Boré & Partner Patentanwälte PartG mbB, 80639 München, DE |
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 303044 P Feb 10, 2010
|
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 317513 P Mar 25, 2010
|
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 229195 P Jul 28, 2009
|
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 333372 P May 11, 2010
|
33 31 32
| Foreign priority | PRC PRNA PRDA
| US 359338 P Jun 28, 2010
|
| Due date | FT FG | Jul 31, 2026 Annual fee for the 17th year
Patent fees |
| Patent division in charge | | 44 |
97 | EP language of publication | ELANG | EN - Englisch |
84 | Designated EP contracting states | EDS | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000002459212 Searchable text:
EP000002459212 Original document:
EP000002459212B1 Searchable text:
EP000002459212B1 Original document:
WO002011017177 Searchable text:
WO002011017177 |
43 | Date of first publication | EVT | Feb 10, 2011 |
| Date of the first transfer into DPMAregister | EREGT | Jul 20, 2012 |
| Date of the (most recent) update in DPMAregister | REGT | Jul 2, 2025 (Show all update days)(Hide all update days)- Jul 2, 2025
- Due date: changed
- Procedures: Procedure relating to EP application, EPO publication of mention of grant , 14.03.2018: new
- Procedures: Procedure relating to EP application, EPO publication of mention of grant , 14.03.2018: deleted
- Aug 9, 2024
- St.36: changed (technical change)
- Jul 20, 2012
- Date of the first transfer into DPMAregister
|
View procedures New applicant/owner details (No.: 8)INID | Criterion | Field | Content
Close details
|
---|
| Type of procedure | VART | New applicant/owner details |
| Legal/procedural status | VST | New applicant/owner details |
| Date of legal/procedural status | VSTT | Aug 13, 2021 |
| Issue number | HN | 38 |
| Year | PJ | 2021 |
| Publication date | VT | Sep 23, 2021 |
| Type of publication | PART | Bibliographic data |
| Part | HT | Part 3 |
71/73 | Applicant/owner | INH | Takeda Pharmaceutical Company Limited, Osaka-shi, Osaka, JP |
71/73 | Previous applicant/owner | INHF | Shire Human Genetic Therapies, Inc., Lexington, Mass., US |
| Date of update of the procedure | REGT | Sep 23, 2021 |